Joinn Laboratories(China)Co Cash Flow Conversion Efficiency
Joinn Laboratories(China)Co cash flow conversion efficiency. Based on the latest financial reports, Joinn Laboratories(China)Co (603127) has a cash flow conversion efficiency ratio of 0.018x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥145.13 Million ≈ $21.24 Million USD) by net assets (CN¥8.12 Billion ≈ $1.19 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Joinn Laboratories(China)Co (2012–2025)
Cash flow conversion efficiency of Joinn Laboratories(China)Co from 2012 to 2025. This chart illustrates how Joinn Laboratories(China)Co's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Joinn Laboratories(China)Co stock quote for real-time trading data and today's change.
Joinn Laboratories(China)Co Cash Flow Conversion Ratio Explained
Joinn Laboratories(China)Co cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Joinn Laboratories(China)Co Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Joinn Laboratories(China)Co ranked by their cash flow conversion efficiency. Also see market value of Joinn Laboratories(China)Co for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Lumen Technologies Inc
NYSE:LUMN
|
-0.653x |
|
Western Superconducting Tech Co Ltd
SHG:688122
|
-0.038x |
|
Mobile World Investment Corp
VN:MWG
|
0.467x |
|
Whitehaven Coal Ltd
AU:WHC
|
0.050x |
|
Axtel S.A.B. de C.V
MX:AXTELCPO
|
0.443x |
|
Copa Holdings S.A
F:C2H
|
0.144x |
|
MARFRIG GL.FOOD.ADR/2O.N.
F:MGP1
|
0.254x |
|
Protector Forsikring ASA
OL:PROT
|
-0.088x |
Annual Cash Flow Conversion Efficiency for Joinn Laboratories(China)Co (2012–2025)
The table below shows the annual cash flow conversion efficiency of Joinn Laboratories(China)Co from 2012 to 2025. Review Joinn Laboratories(China)Co free cash flow efficiency to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CN¥8.33 Billion ≈ $1.22 Billion |
CN¥444.57 Million ≈ $65.05 Million |
0.053x | +27.29% |
| 2024-12-31 | CN¥8.08 Billion ≈ $1.18 Billion |
CN¥338.93 Million ≈ $49.60 Million |
0.042x | -46.37% |
| 2023-12-31 | CN¥8.28 Billion ≈ $1.21 Billion |
CN¥647.73 Million ≈ $94.78 Million |
0.078x | -34.02% |
| 2022-12-31 | CN¥8.19 Billion ≈ $1.20 Billion |
CN¥971.07 Million ≈ $142.10 Million |
0.119x | +23.53% |
| 2021-12-31 | CN¥7.14 Billion ≈ $1.05 Billion |
CN¥685.66 Million ≈ $100.33 Million |
0.096x | -72.58% |
| 2020-12-31 | CN¥1.22 Billion ≈ $179.13 Million |
CN¥428.39 Million ≈ $62.69 Million |
0.350x | +95.48% |
| 2019-12-31 | CN¥827.26 Million ≈ $121.05 Million |
CN¥148.09 Million ≈ $21.67 Million |
0.179x | -33.76% |
| 2018-12-31 | CN¥651.52 Million ≈ $95.34 Million |
CN¥176.08 Million ≈ $25.77 Million |
0.270x | +25.61% |
| 2017-12-31 | CN¥557.79 Million ≈ $81.62 Million |
CN¥120.01 Million ≈ $17.56 Million |
0.215x | -52.89% |
| 2016-12-31 | CN¥260.18 Million ≈ $38.07 Million |
CN¥118.82 Million ≈ $17.39 Million |
0.457x | -10.43% |
| 2015-12-31 | CN¥208.35 Million ≈ $30.49 Million |
CN¥106.23 Million ≈ $15.54 Million |
0.510x | -1.55% |
| 2014-12-31 | CN¥159.07 Million ≈ $23.28 Million |
CN¥82.38 Million ≈ $12.05 Million |
0.518x | +3.63% |
| 2013-12-31 | CN¥121.89 Million ≈ $17.84 Million |
CN¥60.91 Million ≈ $8.91 Million |
0.500x | +143.98% |
| 2012-12-31 | CN¥99.27 Million ≈ $14.53 Million |
CN¥20.33 Million ≈ $2.98 Million |
0.205x | -- |
About Joinn Laboratories(China)Co
Joinn Laboratories(China)Co.,Ltd. provides preclinical and non-clinical services in the United States, the People's Republic of China, and internationally. It operates through three segments: Non-Clinical Studies Services; Clinical Trial and Related Services; and Sales of Research Models. The Non-Clinical Studies Services segment offers drug safety assessment, drug metabolism and pharmacokinetics… Read more